During the meeting, the Press Association also urged the PIB to revive the railways concessions to the accredited journalists, which has been discontinued during the pandemic
Who is Jaideep Bhatnagar; the new Principal DG of PIB
Jaideep Bhatnagar, a 1986-batch Indian Information Service officer, is the new Principal DG of PIB.
India s vaccines DECODED
The Ministry of Information and Broadcasting on Monday announced appointment of Jaideep Bhatnagar as the new Principal Director General of Press Information Bureau. Bhatnagar will take over from Kuldeep Singh Dhatwalia, who superannuated on February 28, 2021.
Who is Jaideep Bhatnagar?
Jaideep Bhatnagar is a 1986-batch Indian Information Service (IIS) officer. Bhatnagar previously served in Doordarshan News as head of the Commercial, Sales and Marketing Division. During his career, he has served as Prasar Bharati Special Correspondent West Asia covering twenty countries before heading the News Services Division of All India Radio.
Jaideep Bhatnagar takes over as Principal Director General of PIB dailyexcelsior.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyexcelsior.com Daily Mail and Mail on Sunday newspapers.
One Chinese vaccine and 4 efficacy rates confuse experts, raise doubts
Premium
A medical worker shows a syringe with the Sinovac Biotech vaccine against the COVID-19 coronavirus at a healthcare centre.
(AFP)
. Updated: 13 Jan 2021, 09:56 AM IST Bloomberg
Uncertainty swirls over the efficacy of the leading Chinese shot, for which four different protection rate numbers have been released in recent weeks
Overlapping efficacy data is not unprecedented in the Covid-19 vaccine race
Share Via
Read Full Story
Days before a global rollout kicks off with the President of Indonesia receiving the Sinovac Biotech Ltd. vaccine on live television, uncertainty swirls over the efficacy of the leading Chinese shot, for which four different protection rate numbers have been released in recent weeks.
China vaccine’s low efficacy due to high-risk group: Sinovac CEO Yin Weidong
Premium
(Photo: Reuters)
. Updated: 13 Jan 2021, 04:19 PM IST Bloomberg
Chinese vaccine developer Sinovac Biotech CEO Yin Weidong said the low efficacy rate of 50.38% from its final-stage trial in Brazil is due to trial participants being medical workers facing a high risk of contracting Covid-19
Share Via
Read Full Story
Chinese vaccine developer Sinovac Biotech Ltd. said that the low efficacy rate of 50.38% from its final-stage trial in Brazil is due to trial participants being medical workers facing a high risk of contracting Covid-19.
In contrast, western vaccines like that developed by Pfizer Inc. and BioNTech SE were tested among volunteers including people from the general population, some of whom were less exposed to the virus in their daily lives compared to medical workers.